Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on T cell engaging bispecific antibodies for solid tumors, has announced an upcoming poster presentation at the AACR Annual Meeting 2025 in Chicago (April 25-30, 2025).
The presentation will feature data on CT-95, the company's clinical asset targeting mesothelin x CD3 TCE. The poster will specifically detail the selection methodology for the first-in-human dose of CT-95, utilizing the minimal anticipated biological effect level (MABEL) approach. The research supports a proposed clinical starting dose of 0.1 μg/kg for CT-95.
Context Therapeutics (Nasdaq: CNTX), un'azienda biofarmaceutica in fase clinica focalizzata su anticorpi bispecifici che attivano le cellule T per i tumori solidi, ha annunciato una prossima presentazione di poster al AACR Annual Meeting 2025 a Chicago (25-30 aprile 2025).
La presentazione presenterà dati su CT-95, l'asset clinico dell'azienda che mira al mesothelin x CD3 TCE. Il poster dettagliarà specificamente la metodologia di selezione per la dose iniziale nell'uomo di CT-95, utilizzando l'approccio del livello minimo di effetto biologico atteso (MABEL). La ricerca supporta una dose iniziale clinica proposta di 0,1 μg/kg per CT-95.
Context Therapeutics (Nasdaq: CNTX), una compañía biofarmacéutica en etapa clínica centrada en anticuerpos bispecíficos que activan células T para tumores sólidos, ha anunciado una próxima presentación de póster en el AACR Annual Meeting 2025 en Chicago (25-30 de abril de 2025).
La presentación contará con datos sobre CT-95, el activo clínico de la compañía que se dirige a mesotelina x CD3 TCE. El póster detallará específicamente la metodología de selección para la primera dosis en humanos de CT-95, utilizando el enfoque del nivel mínimo de efecto biológico anticipado (MABEL). La investigación respalda una dosis inicial clínica propuesta de 0,1 μg/kg para CT-95.
Context Therapeutics (Nasdaq: CNTX)는 고형 종양을 위한 T 세포 결합 이중 특이성 항체에 중점을 둔 임상 단계의 생명공학 회사로, AACR Annual Meeting 2025에서 포스터 발표를 예정하고 있다고 발표했습니다. 이 회의는 시카고에서 2025년 4월 25일부터 30일까지 열립니다.
이번 발표에서는 CT-95에 대한 데이터를 선보일 예정이며, 이는 메소텔린 x CD3 TCE를 타겟으로 하는 회사의 임상 자산입니다. 포스터는 CT-95의 첫 번째 인체 투여 용량에 대한 선택 방법론을 최소 예상 생물학적 효과 수준(MABEL) 접근 방식을 사용하여 구체적으로 설명할 것입니다. 연구는 CT-95에 대해 제안된 초기 임상 용량인 0.1 μg/kg을 뒷받침합니다.
Context Therapeutics (Nasdaq: CNTX), une entreprise biopharmaceutique en phase clinique axée sur des anticorps bispécifiques engageant les cellules T pour les tumeurs solides, a annoncé une prochaine présentation de poster lors de la AACR Annual Meeting 2025 à Chicago (du 25 au 30 avril 2025).
La présentation mettra en avant des données sur CT-95, l'actif clinique de l'entreprise ciblant la mésothelin x CD3 TCE. Le poster détaillera spécifiquement la méthodologie de sélection pour la première dose chez l'homme de CT-95, en utilisant l'approche du niveau d'effet biologique anticipé minimal (MABEL). La recherche soutient une dose clinique de départ proposée de 0,1 μg/kg pour CT-95.
Context Therapeutics (Nasdaq: CNTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf T-Zell-aktivierende bispezifische Antikörper für solide Tumoren konzentriert, hat eine bevorstehende Posterpräsentation auf dem AACR Annual Meeting 2025 in Chicago (25.-30. April 2025) angekündigt.
Die Präsentation wird Daten zu CT-95, dem klinischen Asset des Unternehmens, das auf Mesothelin x CD3 TCE abzielt, enthalten. Das Poster wird speziell die Auswahlmethodik für die erste Dosis am Menschen von CT-95 unter Verwendung des Ansatzes des minimal erwarteten biologischen Effektlevels (MABEL) detaillieren. Die Forschung unterstützt eine vorgeschlagene klinische Startdosis von 0,1 μg/kg für CT-95.
- None.
- None.
PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster regarding the Company’s clinical asset, CT-95, a mesothelin (“MSLN”) x CD3 TCE will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL.
Context will present data highlighting the selection of the first-in-human dose of CT-95, using the minimal anticipated biological effect level (“MABEL”) approach, as required for immune agonist drugs. This is the dose level expected to lead to a minimal biological effect level in humans. The weight of evidence of these data supports the safety of the proposed clinical starting dose of 0.1 μg/kg for CT-95.
Poster Presentation Details:
| Title: | Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelin | |
| Abstract Number: | 2139 | |
| Date and Time: | Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. CT | |
| Session Category: | Clinical Research | |
| Session: | PO.CL06.04 - Therapeutic Antibodies, Including Engineered Antibodies 1 | |
| Location: | Poster Section 34 |
For more information and to view the Company’s abstract, visit the AACR Annual Meeting website.
About CT-95
CT-95 is a MSLN x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately
About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company, its employees and certain AACR presenters to participate in and present at conferences, (ii) our expectation that the dose level will lead to a minimal biological effect level in humans, (iii) the potential benefits, characteristics, safety and side effect profile of our product candidates, and (iv) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
Investor Relations Contact:
Jennifer Minai
Chief Financial Officer
Context Therapeutics Inc.
IR@contexttherapeutics.com
FAQ
What will Context Therapeutics present at AACR 2025 regarding CT-95?
What is the proposed clinical starting dose for Context Therapeutics' CT-95?
When and where will Context Therapeutics (CNTX) present their CT-95 data?
What type of drug is Context Therapeutics' CT-95?
